Hyderabad: City-based drug maker Aurobindo Pharma Limited announced its consolidated financial results for the quarter and year ended March 31, 2023. The pharma major reported Rs 505.9 crore net profit in fourth quarter (Q4) of financial year 2023, a climb by three per cent, as against Rs 491 crore in the previous quarter.
However, the consolidated net profit declined by 12.2 per cent from a profit of Rs 576.1 crore a year ago in the same quarter.
K Nithyananda Reddy, Vice-Chairman and Managing Director, Aurobindo Pharma said: “We saw decent performance in the current quarter, on the back of stable demand and pricing environment across our portfolio and geographies. We remain committed to executing our growth strategies, continuing new launches, and focusing on operational efficiencies.”
Consolidated revenue from operations stood at Rs 6,473 crore in the quarter under review, registering a growth of 11.4 per cent from Rs 5,809.4 crore in Q4 of the previous fiscal. The growth was marginally one per cent as against revenue of Rs 6,407.1 crore in Q3 of FY23.
EBITDA before R&D stood at Rs 1,412.9 crore in Q4, FY23, rising by 0.5 per cent y-o-y and 3.2 per cent q-o-q, respectively. EBITDA margins came in at 15.5 per cent in Q4, FY23, contracting as against 16.8 per cent in Q4, FY22 but were up from a margin of 14.9 per cent in Q3, FY23.
Aurobindo received final approval for 26 ANDAs including four injectable products from the USFDA
